Aspire Biopharma Holdings, Inc.: Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue
Aspire Biopharma Holdings (NASDAQ:ASBP) said it completed its acquisition of Dura Driver Control Systems (DCS), buying 100% for about $30.0 million cash. Aspire also arranged a $22.5 million senior secured revolving credit facility to fund the deal. DCS reported 2025 revenue of $209.5 million and Adjusted EBITDA of $22.3 million.
How this was made
The 30-second read
Why it matters
Completion of the acquisition plus disclosed funding terms ($30.0M cash purchase price and $22.5M senior secured revolving credit facility) is a fresh, tradable catalyst for Aspire’s valuation and near-term financing risk.
Market read
Traders may reprice ASBP on deal-close confirmation, deal size, and the disclosed financing structure, while monitoring leverage and integration execution.
What to watch
The article provides DCS historical revenue/EBITDA but not purchase accounting, expected synergies, integration costs, or how the revolver affects net leverage and interest expense.
Background
Aspire announced and then completed the previously announced acquisition of Dura Driver Control Systems (DCS), a tier-one automotive systems supplier, and arranged a new revolver to fund the deal.
Ticker impact
Aspire Biopharma completed its acquisition of Dura Driver Control Systems for about $30.0M cash and added a $22.5M revolving credit facility.
Near-term upside bias on deal-close optimism, with volatility tied to leverage, integration, and whether DCS margins translate into durable earnings.
The article discloses the completed acquisition, purchase price, DCS revenue/EBITDA scale, and the specific $22.5M revolver used to fund consideration, which are concrete inputs for valuation and risk models.
Market effects
Cross-sector diversification (biopharma into automotive mobility control systems) may shift investor perception of Aspire’s business model and capital allocation priorities.
Limited direct regional read-through; DCS manufacturing footprint spans North America, Europe, and Asia.
Automotive electrification and safety/lightweighting demand is cited as a growth driver for DCS end markets, supporting a global industrial theme.
Counterpoint
The acquisition thesis may be more about financial optics than strategic fit; DCS is an automotive supplier, which could dilute focus and introduce cyclical end-market risk.
Key entities
- public_companyAspire Biopharma Holdings, Inc.
NASDAQ-listed acquirer that completed the DCS acquisition and entered a $22.5M senior secured revolving credit facility.
- businessDura Driver Control Systems (DCS)
Tier-one supplier focused on electronic driver control and mobility control systems; reported $209.5M revenue and $22.3M Adjusted EBITDA in 2025.
- advisorRBW Capital Partners LLC
Exclusive financial advisor to Aspire in connection with the acquisition.
